A Comprehensive Monograph on Latanoprost: Pharmacology, Clinical Efficacy, and Therapeutic Landscape

Executive Summary

Latanoprost, a prostaglandin F2α analog, represents a cornerstone in the modern therapeutic management of glaucoma and ocular hypertension. Its introduction in 1996 revolutionized treatment paradigms due to its potent intraocular pressure (IOP)-lowering efficacy, convenient once-daily dosing regimen, and a favorable systemic safety profile that set it apart from previous standards of care. As an isopropyl ester prodrug, Latanoprost is designed for optimal corneal penetration, where it is hydrolyzed into its active acid form to exert its therapeutic effect. It acts locally by selectively targeting the prostanoid FP receptor, which initiates a cascade of cellular changes that increase aqueous humor outflow primarily through the uveoscleral pathway, an alternative drainage route to the conventional trabecular meshwork.

While highly effective, the clinical profile of Latanoprost is characterized by a well-defined and predictable set of ocular side effects. The most notable of these are conjunctival hyperemia (ocular redness), gradual and permanent changes in iris pigmentation, and reversible changes to eyelashes, including increased length, thickness, and darkness. The therapeutic landscape of Latanoprost has evolved significantly from its initial launch as a single blockbuster brand (Xalatan®). It has matured into a competitive market featuring multiple generic versions, value-added formulations designed to improve tolerability, and strategic fixed-dose combinations aimed at enhancing efficacy. This evolution reflects a growing clinical focus on mitigating long-term ocular surface toxicity, leading to the development of benzalkonium chloride (BAK)-free (Xelpros®) and entirely preservative-free (Iyuzeh™) formulations. Furthermore, fixed-dose combinations with agents like timolol and the novel Rho kinase inhibitor netarsudil (Rocklatan®) provide powerful options for patients requiring greater IOP reduction.

Current and future research is focused on overcoming the inherent limitations of topical eye drop therapy, particularly patient non-adherence and poor bioavailability. Innovations are proceeding along two parallel tracks: the development of novel formulations, such as hyaluronic acid-coated liposomes to enhance drug penetration and protect the ocular surface, and the investigation of advanced drug delivery systems. Among the most promising of these is the Latanoprost-eluting contact lens, which offers the potential for continuous, week-long drug delivery, thereby eliminating the burden of daily self-administration. This report provides an exhaustive analysis of Latanoprost, synthesizing the available chemical, pharmacological, clinical, and regulatory evidence to create a definitive monograph on its established role and future potential in ophthalmology.

Chemical Profile and Formulation Science

Identification and Nomenclature

To establish the precise chemical identity of Latanoprost, which is fundamental for scientific, clinical, and regulatory discourse, a comprehensive set of identifiers is utilized. The molecule is recognized globally by its generic names, Latanoprost and its Latin equivalent, Latanoprostum.[1] Its unique identifiers in major chemical and pharmacological databases provide an unambiguous reference for researchers and clinicians. These include its DrugBank Accession Number, DB00654, and its Chemical Abstracts Service (CAS) Registry Number, 130209-82-4.[1]

The structural identity of Latanoprost is defined by its systematic chemical nomenclature according to the International Union of Pure and Applied Chemistry (IUPAC), which is propan-2-yl (Z)-7-cyclopentyl]hept-5-enoate.[2] Other formal chemical names are also used, such as 9α,11α,15R-trihydroxy-17-phenyl-18,19,20-trinor-prost-5Z-en-1-oic acid, isopropyl ester, which highlights its relationship to prostanoic acid.[4] For computational and database purposes, its structure is encoded in various formats, including the International Chemical Identifier (InChI) and the Simplified Molecular Input Line Entry System (SMILES).[2] The consolidation of these identifiers, as presented in Table 1, provides a single point of truth for cross-database queries and literature searches, forming the foundational data upon which all subsequent pharmacological and clinical discussions are built.

Table 1: Latanoprost Chemical and Physical Identifiers

Identifier Type	Value	Source(s)
Generic Name	Latanoprost	1
DrugBank ID	DB00654	1
CAS Number	130209-82-4	1
IUPAC Name	propan-2-yl (Z)-7-cyclopentyl]hept-5-enoate	2
Chemical Formula	C26​H40​O5​	1
InChI	InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1	2
InChIKey	GGXICVAJURFBLW-CEYXHVGTSA-N	2
SMILES	CC(C)OC(=O)CCC/C=C\C[C@H]1C@HO

Molecular Structure and Physicochemical Properties

Latanoprost is a small molecule with the chemical formula C26​H40​O5​. It has an average molecular weight of 432.59 g/mol and a monoisotopic mass of 432.28757439 Da, reflecting its precise atomic composition. In its pure form, Latanoprost is described as a clear, thick, colorless to slightly yellow oil, or a liquid with a high boiling point of 583.8 °C.

The physicochemical properties of Latanoprost are critical to its function as an ophthalmic drug. It has very low solubility in water, measured at approximately 0.0129 g/L. This poor aqueous solubility stems from its lipophilic character, which is conferred by its long hydrocarbon chains and terminal phenyl group. This lipophilicity is essential for the drug's ability to penetrate the lipid-rich layers of the cornea. The molecule's design as an isopropyl ester is a key structural modification that enhances this property. By converting the carboxylic acid group of the parent molecule into an ester, the polarity is reduced, making it more favorable for passage across biological membranes. This chemical strategy, however, necessitates specific formulation approaches to keep the lipophilic drug solubilized in an aqueous eye drop vehicle.

For research and manufacturing purposes, Latanoprost is supplied at high purity levels, typically greater than or equal to 97% or 98%. The stability of the pure compound requires cold storage, often at -20°C. In contrast, the formulated ophthalmic products have specific storage requirements that vary by brand and formulation. Unopened bottles of the original brand, Xalatan®, require refrigeration, but once opened, can be stored at room temperature for up to six weeks. The preservative-free formulation Iyuzeh™ is stable at room temperature even before opening, a significant logistical advantage.

Formulations and Excipients: The Critical Role of Preservatives

Latanoprost is commercially available for ophthalmic use as a 0.005% (50 µg/mL) sterile preparation, formulated as either a solution or an emulsion. The evolution of these formulations reflects a significant trend in ophthalmology toward improving the long-term tolerability of chronic medications.

The original formulation of Latanoprost (Xalatan®) and its subsequent generic versions traditionally contained the preservative benzalkonium chloride (BAK). BAK is a quaternary ammonium compound that serves as a highly effective broad-spectrum antimicrobial agent, essential for maintaining sterility in multi-dose ophthalmic bottles. However, the use of BAK is a double-edged sword. While it prevents microbial contamination, it is also a detergent that can disrupt the tear film and is known to be toxic to the cells of the cornea and conjunctiva. In patients requiring lifelong glaucoma therapy, chronic exposure to BAK can lead to or exacerbate ocular surface disease (OSD), a condition characterized by symptoms of burning, stinging, foreign body sensation, and dry eye. This direct link between the chemical solution to the biological problem of corneal penetration (the lipophilic prodrug) and the subsequent pharmaceutical problem of formulation (requiring a solubilizing agent like BAK) has been a primary driver of innovation in Latanoprost therapy.

The growing clinical recognition of preservative-induced OSD created a clear unmet need for better-tolerated alternatives, leading to a new wave of product development. This market evolution, driven by clinical need, has produced several value-added formulations:

• BAK-Free Emulsion (Xelpros®): Approved by the FDA in 2018, Xelpros® was the first Latanoprost formulation available in the U.S. that was not formulated with BAK. It utilizes an emulsion technology to solubilize the active ingredient, thereby avoiding the most common cause of preservative-related ocular surface toxicity.
• Preservative-Free Solution (Iyuzeh™): Taking the concept a step further, Iyuzeh™ was approved in 2022 as the first completely preservative-free formulation of Latanoprost in the U.S. This formulation successfully addressed the technical challenge of solubilizing and stabilizing Latanoprost in an aqueous solution without any preservatives and, importantly, without the need for refrigeration. Phase III clinical trials demonstrated that Iyuzeh™ had non-inferior IOP-lowering efficacy compared to BAK-preserved Latanoprost, while also showing statistically significant improvements in the signs and symptoms of OSD.

Beyond the active ingredient and preservatives, these ophthalmic formulations contain various excipients to ensure they are safe and comfortable for ocular use. These typically include agents like sodium chloride to make the solution isotonic with tears, and buffering agents such as sodium phosphate monobasic and dibasic to maintain a stable pH that is close to physiological levels, minimizing stinging upon instillation.

Comprehensive Pharmacological Profile

Pharmacodynamics (Mechanism of Action)

The therapeutic effect of Latanoprost is derived from its activity as a potent and selective prostanoid FP receptor agonist. It is a synthetic structural analog of the naturally occurring prostaglandin F2α (

PGF2α​). The biologically active form of the drug, latanoprost acid, binds with high affinity to the prostaglandin F receptor, which is a G-protein coupled receptor located in various ocular tissues, most importantly the ciliary muscle.

The primary mechanism by which Latanoprost reduces intraocular pressure is fundamentally different from that of older classes of glaucoma medications like beta-blockers or miotics. Instead of reducing the production of aqueous humor or increasing its drainage through the conventional (trabecular) pathway, Latanoprost enhances aqueous humor outflow through the uveoscleral pathway. This is often referred to as the "unconventional" or "alternate" outflow route.

Activation of the FP receptors by latanoprost acid initiates a complex cascade of downstream cellular and molecular events that culminate in reduced resistance to aqueous outflow. The proposed mechanisms include:

1. Relaxation of the Ciliary Smooth Muscle: Binding of latanoprost acid to FP receptors on ciliary muscle cells leads to their relaxation. This relaxation widens the interstitial spaces within the ciliary body, reducing hydraulic resistance and facilitating the passage of aqueous humor from the anterior chamber into the suprachoroidal space.
2. Extracellular Matrix (ECM) Remodeling: Latanoprost has been shown to upregulate the expression and activity of matrix metalloproteinases (MMPs), such as MMP-1, MMP-3, and MMP-9, within the ciliary muscle and sclera. These enzymes degrade components of the extracellular matrix, including collagen. This controlled remodeling of the connective tissue of the uveoscleral pathway is thought to increase its porosity and permeability, further enhancing the outflow of aqueous fluid.

Latanoprost exhibits a high degree of selectivity for the FP receptor, which is a key factor in its favorable safety profile. While it possesses greater selectivity for the FP receptor than natural PGF2α​, it also demonstrates some minor agonist activity at the EP1 and EP3 prostanoid receptors. However, it has little to no effect at other prostanoid receptors such as EP2, DP, IP, and TP. This specificity minimizes off-target effects and contributes to its better tolerability compared to less selective prostaglandin compounds. The mechanism of action, focused on remodeling the uveoscleral pathway, is not only central to its efficacy but also provides a plausible explanation for some of its unique ocular side effects. The broad cellular stimulation in the anterior segment that leads to increased outflow can also affect nearby cells, such as melanocytes in the iris and hair follicles of the eyelashes, leading to the characteristic side effects of pigmentation and hypertrichosis.

Pharmacokinetics (Absorption, Distribution, Metabolism, and Excretion - ADME)

The pharmacokinetic profile of Latanoprost is a prime example of a "smart drug" design for topical ophthalmic therapy, engineered to maximize local efficacy in the eye while minimizing systemic exposure and potential side effects. This is achieved through its design as a prodrug that is activated at the target site and rapidly eliminated from the rest of the body.

Absorption and Activation: Latanoprost is administered as an isopropyl ester prodrug. This formulation is more lipophilic than the parent acid, allowing it to be rapidly and effectively absorbed through the lipid layers of the cornea following topical instillation. During its transit through the cornea, the prodrug is completely hydrolyzed by ubiquitous esterase enzymes into its biologically active form,

latanoprost acid. This site-specific activation ensures that the highest concentration of the active drug is delivered directly to the anterior chamber of the eye.

Distribution: Following its activation, peak concentrations of latanoprost acid in the aqueous humor are achieved approximately two hours after administration. The volume of distribution in humans is low, at 0.16 ± 0.02 L/kg, indicating that the drug does not distribute extensively into peripheral tissues. Systemic absorption from the conjunctival sac is minimal, which is a key factor in its excellent systemic safety profile.

Metabolism: Any latanoprost acid that does reach the systemic circulation is subject to rapid and extensive first-pass metabolism in the liver. The primary metabolic pathway is fatty acid β-oxidation, which breaks down the molecule into shorter, inactive metabolites, principally 1,2-dinor and 1,2,3,4-tetranor latanoprost.

Excretion: The inactive metabolites of Latanoprost are primarily eliminated from the body via the kidneys. Following topical administration, approximately 88% of the administered dose can be recovered in the urine as metabolites. A minor fraction, around 15%, may be eliminated through fecal excretion.

Half-life and Clearance: The pharmacokinetic properties of Latanoprost are characterized by a striking difference between its local and systemic behavior. The elimination half-life of latanoprost acid from the plasma is remarkably short, estimated to be only 17 minutes. This rapid systemic clearance (approximately 7 mL/min/kg) prevents the drug from accumulating in the body and causing systemic side effects. In contrast, the drug has a much longer effective half-life within the eye, estimated at 2–3 hours. This prolonged local residence time is what allows the drug to exert a sustained IOP-lowering effect for at least 24 hours, making a convenient once-daily dosing schedule possible. This elegant pharmacokinetic profile—local activation, prolonged local effect, and rapid systemic inactivation—is the foundation of Latanoprost's high therapeutic index and its success as a first-line glaucoma therapy.

Table 2: Summary of Latanoprost Pharmacokinetic Parameters

Parameter	Value / Description	Significance	Source(s)
Nature	Isopropyl ester prodrug	Enhances corneal penetration; requires hydrolysis for activation.
Activation Site	Cornea (via esterases)	Delivers active drug directly to the anterior segment.
Time to Peak Concentration (Tmax)	~2 hours (in aqueous humor)	Correlates with the onset of IOP-lowering effect.
Ocular Half-life	2–3 hours	Allows for a prolonged local effect, enabling once-daily dosing.
Plasma Half-life	~17 minutes	Extremely rapid elimination from systemic circulation, minimizing systemic side effects.
Systemic Clearance	7 mL/min/kg	High clearance contributes to the low systemic exposure.
Metabolism	Hepatic β-oxidation	Inactivates any systemically absorbed drug.
Primary Excretion Route	Renal (as metabolites)	~88% of dose recovered in urine.

Clinical Efficacy and Therapeutic Applications

FDA-Approved Indications

Latanoprost is officially approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in two primary patient populations: those with open-angle glaucoma (OAG) and those with ocular hypertension (OHT). Since its initial approval, it has become a first-line therapeutic choice for these conditions due to its potent efficacy and favorable safety profile. Its importance in global ophthalmic care is underscored by its inclusion on the World Health Organization's List of Essential Medicines and its widespread use, with over 9 million prescriptions in the United States in 2022 alone.

The clinical efficacy of Latanoprost is well-established through numerous large-scale clinical trials. Pivotal studies have consistently demonstrated its ability to produce substantial and sustained IOP reductions. Across various trials, Latanoprost has been shown to lower IOP by a range of 22% to 39% from baseline over treatment periods of one to twelve months. In controlled trials involving patients with a mean baseline IOP in the range of 24–25 mmHg, treatment with Latanoprost resulted in mean IOP reductions of 6 to 8 mmHg over a six-month period. Other analyses have reported an average IOP drop of 30% to 35%.

The pharmacodynamic timeline of Latanoprost is predictable and supports its convenient dosing schedule. The IOP-lowering effect begins within 3 to 4 hours of instillation, reaches its maximum effect at 8 to 12 hours, and, critically, the effect is maintained for at least 24 hours. This duration of action is what allows for effective IOP control with a simple once-daily administration.

Off-Label and Investigational Uses

The robust mechanism of action and favorable safety profile of Latanoprost have led to its widespread off-label use in a variety of other glaucomatous conditions where its primary mechanism—enhancing uveoscleral outflow—is clinically advantageous. This utility stems from its ability to bypass the trabecular meshwork, the primary site of pathology in many forms of glaucoma.

Chronic Angle-Closure Glaucoma (CACG)

In patients with CACG, the drainage angle is physically compromised by peripheral anterior synechiae. Even after a laser peripheral iridotomy (PI) is performed to relieve pupillary block, many patients continue to have elevated IOP due to pre-existing damage to the trabecular meshwork. In this context, Latanoprost has proven to be highly effective. Clinical studies have shown it to be significantly more effective than the beta-blocker timolol in post-PI CACG patients. One comparative trial reported an IOP reduction of 8.8 mmHg with Latanoprost versus only 5.7 mmHg with timolol. A comprehensive meta-analysis of randomized controlled trials in CACG confirmed that Latanoprost is superior to timolol in IOP reduction. The same analysis found it to be marginally less potent than bimatoprost and travoprost, but with the significant advantage of being better tolerated, with a lower incidence of side effects like conjunctival hyperemia. The efficacy of Latanoprost in this condition is directly attributable to its mechanism, which provides an effective "alternate drain" for aqueous humor when the conventional trabecular route is obstructed.

Normal-Tension Glaucoma (NTG)

The management of NTG is challenging, as it involves progressive optic nerve damage despite IOP levels being within the statistically "normal" range. The therapeutic goal is to achieve a significant percentage reduction of this baseline IOP, often by 30% or more, to slow disease progression. Latanoprost is frequently used off-label for this purpose. A long-term study in NTG patients demonstrated that Latanoprost produced a sustained hypotensive effect, with a 17% mean decrease in average diurnal IOP and a 19% decrease in maximum diurnal IOP. However, the study also highlighted a key limitation: Latanoprost monotherapy was insufficient to achieve the desired 30% IOP reduction in the majority of patients, suggesting that combination therapy may be necessary for many individuals with NTG. The choice of agent in NTG is also influenced by other factors, such as ocular perfusion pressure, with some evidence suggesting that beta-blockers may be less ideal due to their potential to lower systemic blood pressure.

Pediatric Glaucoma

Pediatric glaucoma is a rare and difficult-to-treat condition with few FDA-approved medications. Latanoprost is commonly used off-label in this population. The evidence base for this use is limited. The official FDA labeling states that safety and efficacy have not been established in pediatric patients. However, pharmacokinetic studies have been conducted to assess systemic exposure in children. These studies found that while Latanoprost is rapidly eliminated from the plasma in all age groups, infants under the age of three may have higher peak plasma concentrations compared to older children, primarily due to their smaller body weight and blood volume. Despite the lack of large-scale efficacy trials, reports from clinical practice and smaller studies suggest it is an effective IOP-lowering agent in children.

Steroid-Induced Glaucoma

This condition is a form of secondary open-angle glaucoma caused by the use of corticosteroids, which induce biochemical and structural changes in the trabecular meshwork that increase outflow resistance. As with other glaucomas where the trabecular meshwork is compromised, Latanoprost's uveoscleral mechanism is advantageous. A prospective clinical trial specifically investigating its use in newly diagnosed steroid-induced glaucoma found that Latanoprost monotherapy was both safe and effective, producing a significant 28% reduction in IOP from baseline.

Pigmentary Glaucoma

In pigmentary glaucoma, pigment granules shed from the posterior iris surface accumulate in and obstruct the trabecular meshwork. The evidence for Latanoprost use in this specific condition is sparse within the available literature. Some clinical trial protocols explicitly exclude patients with pigmentary glaucoma, likely to ensure a more homogeneous study population and avoid potential confounding factors. Other real-world observational studies may include a small number of such patients, but dedicated research on its efficacy in this subtype is limited. Its use in pigmentary glaucoma is therefore based more on mechanistic rationale and clinical extrapolation than on robust trial evidence.

Dosing, Administration, and Patient Adherence

The standard and recommended dosage for Latanoprost is one drop of the 0.005% formulation instilled into the conjunctival sac of the affected eye(s) once daily, preferably in the evening. Evening administration is generally favored as some studies suggest it may provide a slightly more consistent 24-hour IOP control compared to morning dosing.

A critical and counterintuitive clinical point is that increasing the dosing frequency does not improve efficacy. In fact, administering Latanoprost more than once a day can lead to a paradoxical reduction in its IOP-lowering effect. This phenomenon is thought to be due to downregulation or desensitization of the FP receptors from overstimulation, which attenuates the therapeutic response. This makes patient education on strict adherence to the once-daily regimen not just a matter of convenience, but a mechanistic necessity for optimal treatment.

Proper administration technique is crucial for maximizing efficacy and minimizing local and systemic side effects. Patients should be instructed to:

1. Wash their hands thoroughly before use.
2. Gently pull down the lower eyelid to create a small pocket.
3. Instill a single drop without allowing the dropper tip to touch the eye or any other surface to prevent contamination.
4. After instillation, close the eye and apply gentle pressure to the tear duct (nasolacrimal occlusion) for 2 to 3 minutes. This technique helps to keep the medication in the eye for longer and reduces its drainage into the nasal passages and subsequent systemic absorption.

When Latanoprost is used as part of a multi-drug regimen, patients should wait at least 5 minutes between the instillation of different eye drops to prevent one drop from washing out the other. Patients who wear contact lenses must remove them before applying Latanoprost and should wait at least 15 minutes before reinserting them. The convenience of the once-daily dosing schedule is a major advantage of Latanoprost and contributes significantly to better long-term patient adherence compared to medications requiring multiple daily doses.

Safety, Tolerability, and Risk Management

Adverse Effects Profile

Latanoprost is generally well-tolerated, particularly with respect to systemic effects. Its adverse effect profile is dominated by local ocular events, which are common but typically mild to moderate in severity.

Ocular Adverse Effects (Common)

• Conjunctival Hyperemia: Ocular redness is a very common class effect of prostaglandin analogs, resulting from vasodilation of conjunctival blood vessels. While the incidence can be high, studies consistently show that Latanoprost is associated with less frequent and less severe hyperemia compared to other agents in its class, such as bimatoprost and travoprost.
• Iris Pigmentation Changes: This is one of the most well-known side effects. Latanoprost can cause a gradual, and likely permanent, increase in the brown pigment of the iris. This change is caused by an increase in the number of melanosomes within the iris stromal melanocytes. It is most noticeable in patients with mixed-color irides (e.g., green-brown, blue-brown, yellow-brown) and occurs slowly over months to years. This is a critical point for patient counseling, especially in cases of unilateral treatment where it can lead to heterochromia (a difference in color between the two eyes).
• Eyelash Changes (Hypertrichosis): Latanoprost frequently causes changes to the eyelashes of the treated eye, including increased length, thickness, number, and darkening of the lashes. Unlike the iris changes, these effects are generally reversible upon discontinuation of the medication. This particular side effect has been famously repurposed for cosmetic applications.
• Periorbital Pigmentation: A darkening of the skin of the eyelids and around the eye can also occur. This effect may be permanent. Wiping away excess medication from the eyelid after instillation may help reduce this effect.
• Ocular Irritation: Symptoms such as stinging or burning upon instillation, itching, a foreign body sensation, and blurred vision are commonly reported.

Ocular Adverse Effects (Less Common/Serious)

While less frequent, more serious ocular adverse events have been reported. These include the development or exacerbation of intraocular inflammation, such as iritis and uveitis. The development of macular edema, particularly cystoid macular edema (CME), has been observed, primarily in patients with pre-existing risk factors such as aphakia (absence of the lens), pseudophakia with a ruptured posterior lens capsule, or a history of diabetic retinopathy. Reactivation of herpes simplex keratitis has also been reported in susceptible individuals.

Systemic Adverse Effects

Systemic side effects are rare with Latanoprost, a direct consequence of its low systemic absorption and rapid hepatic metabolism. This favorable systemic safety profile is a major advantage over other glaucoma drug classes, such as topical beta-blockers, which can have significant cardiovascular and respiratory effects. Although very infrequent (reported in <1% of patients), asthma, exacerbation of asthma, and dyspnea have been associated with Latanoprost use.

Contraindications, Warnings, and Precautions

The use of Latanoprost is contraindicated in patients with a known hypersensitivity to Latanoprost itself, to benzalkonium chloride (a component of many preserved formulations), or to any other excipient in the product.

Several warnings and precautions should be observed when prescribing Latanoprost:

• Intraocular Inflammation: It should be used with caution in patients with active intraocular inflammation (e.g., iritis, uveitis) as prostaglandin analogs can disrupt the blood-aqueous barrier and potentially worsen the condition.
• Macular Edema: Caution is advised when treating patients with known risk factors for macular edema, as noted above.
• Herpetic Keratitis: Patients with a history of herpes simplex virus keratitis should be treated with caution, as reactivation of the virus has been reported.
• Pregnancy and Lactation: Latanoprost is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Because prostaglandins can theoretically increase uterine tone and have uterotonic effects, other classes of glaucoma medication are generally preferred during pregnancy. It is not known whether Latanoprost or its metabolites are excreted in human milk, so caution should be exercised when administered to a nursing woman.

Significant Drug Interactions

While Latanoprost has few systemic interactions, several clinically important interactions with other ophthalmic products exist:

• Other Prostaglandin Analogs: The concomitant use of Latanoprost with another prostaglandin analog (e.g., bimatoprost, travoprost) is not recommended. This combination can lead to a paradoxical increase in intraocular pressure rather than an additive effect. This counterintuitive interaction is thought to result from competitive binding at the same FP receptor or rapid receptor desensitization from oversaturation, highlighting the importance of understanding shared mechanisms of action.
• Thimerosal: A precipitation reaction can occur if Latanoprost eye drops are administered concurrently with ophthalmic products containing the preservative thimerosal. To avoid this, the administration of these drugs should be separated by at least five minutes.
• Topical NSAIDs: The use of topical non-steroidal anti-inflammatory drugs (NSAIDs) such as ketorolac, diclofenac, or flurbiprofen may, in some cases, reduce the IOP-lowering efficacy of Latanoprost.
• Systemic Drug Interactions: One identified interaction is with Baricitinib, a Janus kinase inhibitor. The serum concentration of Baricitinib may be increased when it is used in combination with Latanoprost, warranting potential monitoring.

Comparative Analysis and Therapeutic Positioning

Efficacy and Safety vs. Other Prostaglandin Analogs (Bimatoprost, Travoprost)

Within the class of prostaglandin analogs (PGAs), Latanoprost, bimatoprost, and travoprost are the most widely used agents. The central clinical question for practitioners is whether a clear superiority exists among them. The extensive body of evidence from head-to-head trials and meta-analyses indicates that the choice involves a nuanced trade-off between maximal IOP-lowering efficacy and patient tolerability.

Efficacy (IOP Reduction)

All three PGAs are highly effective IOP-lowering agents and have demonstrated superior efficacy compared to the previous gold standard, timolol. However, subtle but consistent differences in potency have been observed. A general consensus from multiple meta-analyses and comparative trials suggests a slight hierarchy in IOP-lowering power. Bimatoprost (0.03% or 0.01%) is often found to produce the greatest mean IOP reduction, showing a statistically significant, though often small (in the range of 1–2 mmHg), advantage over both Latanoprost and travoprost. For instance, one prospective study found the mean IOP reduction at 12 weeks to be 8.8 mmHg (35.9%) for bimatoprost, compared to 7.6 mmHg (30.8%) for travoprost and 7.3 mmHg (29.9%) for Latanoprost. The efficacy of Latanoprost and travoprost is generally considered to be comparable, with most studies finding no clinically significant difference between them.

Tolerability (Side Effects)

The primary differentiator among the three leading PGAs is their tolerability profile, specifically the incidence and severity of ocular side effects. Latanoprost consistently emerges as the best-tolerated agent in the class. Numerous studies have shown that it is associated with a significantly lower incidence of conjunctival hyperemia (ocular redness) compared to both bimatoprost and travoprost. This superior tolerability profile is a key clinical advantage, as side effects are a major driver of patient non-compliance and discontinuation of therapy. Evidence suggests that patients treated with Latanoprost demonstrate better adherence and persist with their therapy for longer periods than those prescribed other PGAs. Bimatoprost and travoprost tend to have higher rates of ocular adverse events, with hyperemia being the most prominent.

This evidence places the three main PGAs on a clinical spectrum: Bimatoprost offers the highest potential efficacy but with the lowest tolerability, while Latanoprost offers excellent efficacy with the highest tolerability. This reframes the clinical choice from a simple question of "which is best?" to a more personalized decision of "which is best for this particular patient?" For a patient with very high IOP or advanced disease who requires maximal pressure reduction, the slightly greater efficacy of bimatoprost may be prioritized. Conversely, for a patient with mild to moderate disease, a history of sensitivity to medications, or pre-existing ocular surface disease, the superior tolerability of Latanoprost makes it a more suitable choice, as it maximizes the likelihood of long-term adherence.

Table 3: Comparative Profile of Prostaglandin Analogs (Latanoprost, Bimatoprost, Travoprost)

Feature	Latanoprost (0.005%)	Bimatoprost (0.03%)	Travoprost (0.004%)
IOP Lowering Efficacy	Highly effective. Mean reduction ~7.3–8.6 mmHg or ~30–35% from baseline.	Generally considered the most potent. Mean reduction ~8.7–8.8 mmHg or ~36% from baseline.	Highly effective. Mean reduction ~7.6 mmHg or ~31% from baseline.
Comparison	Efficacy is generally comparable to travoprost. Slightly less potent than bimatoprost.	Statistically superior IOP reduction compared to latanoprost and travoprost in several meta-analyses.	Efficacy is generally comparable to latanoprost.
Conjunctival Hyperemia	Lowest incidence among the three. Best-tolerated profile.	Highest incidence of hyperemia.	Higher incidence of hyperemia than latanoprost.
Overall Tolerability	Best overall tolerability and patient persistence.	Less tolerated than latanoprost due to higher rates of side effects.	Less tolerated than latanoprost due to higher rates of side effects.
Clinical Positioning	Excellent first-line choice, especially for patients sensitive to side effects or with OSD.	Preferred when maximal IOP reduction is the primary goal, and the patient can tolerate the side effects.	An effective alternative to latanoprost and bimatoprost.

Role of Fixed-Dose Combinations (FDCs)

For patients who do not achieve their target IOP on monotherapy, the next step in treatment often involves adding a second medication from a different class. Fixed-dose combinations (FDCs) simplify this by combining two active ingredients in a single bottle, which can improve patient adherence and reduce the preservative load compared to using two separate bottles.

• Latanoprost/Timolol (e.g., Xalacom®): This long-standing FDC combines Latanoprost with the beta-blocker timolol. It offers a powerful dual-mechanism approach by both increasing aqueous outflow (Latanoprost) and decreasing aqueous production (timolol). Clinical trials have confirmed that this combination provides significantly greater IOP reduction than either of its components used as monotherapy.
• Latanoprost/Netarsudil (Rocklatan®): Approved in 2019, this innovative FDC represents a strategic move to maximize efficacy for patients failing monotherapy. It combines Latanoprost with netarsudil, a first-in-class Rho kinase (ROCK) inhibitor. This combination targets all known outflow pathways: Latanoprost enhances uveoscleral outflow, while netarsudil enhances outflow through the primary, trabecular meshwork pathway. The result is a significantly more potent IOP-lowering effect, with the FDC reducing IOP by up to 3 mmHg more than either Latanoprost or netarsudil alone. Switching patients from Latanoprost-based regimens to this FDC can provide substantial additional IOP lowering. This superior efficacy, however, comes at the cost of tolerability, as the FDC carries the side effect profiles of both drugs and is associated with a significantly higher rate of conjunctival hyperemia than Latanoprost monotherapy.

Cost-Effectiveness Analysis

The cost-effectiveness of Latanoprost relative to its comparators is a complex issue that varies significantly based on geographical location, the local healthcare system, and, most importantly, drug pricing (i.e., brand name vs. generic availability). Early studies, conducted when all drugs were branded, yielded mixed results. Some analyses from Scandinavian countries found Latanoprost to be a dominant option, being both less expensive and more effective than bimatoprost and travoprost. In contrast, other analyses based on different pricing models concluded that bimatoprost was the most cost-effective choice.

The widespread availability of generic Latanoprost since 2011 has fundamentally altered this landscape. In most markets today, generic Latanoprost is the most inexpensive PGA, making it a highly cost-effective first-line treatment option. When compared to timolol, another low-cost generic, Latanoprost is more expensive but also more effective at lowering IOP. The resulting incremental cost-effectiveness ratio (ICER), or the cost per quality-adjusted life-year (QALY) gained, varies widely by country but often falls within acceptable thresholds for a first-line therapy. In some health systems, non-pharmacological options like selective laser trabeculoplasty (SLT) have been shown to have a lower long-term economic impact than chronic therapy with eye drops like Latanoprost.

Regulatory and Commercial Overview

Global Brand Landscape and Market Presence

The commercial history of Latanoprost is a classic story of a blockbuster drug's lifecycle. It was first introduced to the market under the pioneer brand name Xalatan®, developed by Pharmacia & Upjohn (later acquired by Pfizer). For over a decade, Xalatan® dominated the glaucoma market as the leading prostaglandin analog.

Following the expiration of its primary patents, the market opened to competition. Since March 2011, numerous pharmaceutical companies have launched generic Latanoprost 0.005% ophthalmic solutions. Major manufacturers of generic versions include Sandoz, Bausch + Lomb, and Amring Pharmaceuticals, among others. The entry of generics led to a significant reduction in cost and expanded patient access.

In response to generic competition, innovation shifted towards creating "value-added" or differentiated branded products based on the Latanoprost molecule. These include:

• Xelpros®: A 0.005% ophthalmic emulsion from Sun Pharma, notable for being the first Latanoprost formulation free of the preservative benzalkonium chloride (BAK).
• Iyuzeh™: A 0.005% ophthalmic solution from Thea Pharma, which is the first completely preservative-free Latanoprost formulation approved in the U.S..
• Catiolanze: A brand name for which a positive opinion for marketing authorization was adopted by the European Medicines Agency in 2023.

The Latanoprost molecule is also a key component in several successful fixed-dose combination (FDC) products:

• Rocklatan® (in the U.S.) and Roclanda® (in Europe): An FDC of Latanoprost and the Rho kinase inhibitor netarsudil, marketed by Aerie Pharmaceuticals (now part of Alcon).
• Xalacom®: A well-established FDC of Latanoprost and the beta-blocker timolol.

FDA Approval Timeline and Key Milestones

The regulatory journey of Latanoprost and its subsequent formulations in the United States provides a clear timeline of its clinical and commercial evolution. This history demonstrates a progression from initial innovation to market maturity, followed by strategic differentiation through improved formulations and novel combinations.

• June 5, 1996: The U.S. Food and Drug Administration (FDA) grants initial approval to Xalatan® (latanoprost) 0.005% solution. It was initially approved as a second-line treatment for patients who were intolerant of or insufficiently responsive to other IOP-lowering medications.
• 2002: The FDA expands the indication for Xalatan®, approving it as a first-line treatment for open-angle glaucoma and ocular hypertension. This milestone solidified its position as a cornerstone of glaucoma therapy.
• March 22, 2011: The first generic versions of Latanoprost 0.005% ophthalmic solution receive FDA approval. This marked the end of market exclusivity for Xalatan® and ushered in an era of widespread, lower-cost access to the molecule.
• September 12, 2018: The FDA approves Xelpros® (latanoprost) 0.005% ophthalmic emulsion. This was a significant development as it was the first BAK-free formulation of Latanoprost, offering a new option for patients with ocular surface disease or sensitivity to preservatives.
• March 12, 2019: The FDA approves Rocklatan®, a fixed-dose combination of netarsudil 0.02% and latanoprost 0.005%. This approval introduced a novel, dual-mechanism therapy that targets both the trabecular and uveoscleral outflow pathways, providing a powerful option for patients needing significant IOP reduction.
• December 13, 2022: The FDA approves Iyuzeh™ (latanoprost) 0.005% ophthalmic solution. This marked another key advancement in formulation science, as Iyuzeh™ became the first completely preservative-free version of Latanoprost available in the U.S., further addressing the clinical need for well-tolerated long-term therapies.

Table 4: Major Latanoprost Formulations and FDA Approval History in the U.S.

Product Name(s)	Manufacturer(s)	Composition / Key Feature	FDA Approval Date	Source(s)
Xalatan®	Pharmacia & Upjohn (Pfizer)	0.005% Latanoprost solution with BAK	June 5, 1996
Generic Latanoprost	Multiple (e.g., Sandoz, Bausch + Lomb)	0.005% Latanoprost solution with BAK	March 22, 2011 (First approvals)
Xelpros®	Sun Pharma	0.005% Latanoprost emulsion (BAK-free)	September 12, 2018
Rocklatan®	Aerie Pharmaceuticals (Alcon)	0.005% Latanoprost + 0.02% Netarsudil (FDC)	March 12, 2019
Iyuzeh™	Thea Pharma	0.005% Latanoprost solution (Preservative-free)	December 13, 2022

Future Directions and Innovations in Latanoprost Therapy

While Latanoprost is a mature and highly effective drug, research and development continue to address its remaining limitations, primarily those related to topical administration: patient non-adherence, poor bioavailability, and ocular surface toxicity. Innovation is advancing on two parallel frontiers: the creation of novel molecules inspired by Latanoprost and the development of advanced delivery systems for the existing molecule.

Novel Formulations for Enhanced Delivery and Tolerability

Beyond simply removing preservatives, researchers are exploring advanced formulations designed to improve the pharmacokinetic profile of Latanoprost and enhance its interaction with the ocular surface. A promising area of investigation is the use of nanotechnology-based drug carriers. One recent study explored the potential of preservative-free, hyaluronic acid-coated Latanoprost-loaded liposomes. This sophisticated formulation encapsulates Latanoprost within lipid vesicles (liposomes), which are then coated with hyaluronic acid, a mucoadhesive polymer naturally found in the eye.

The findings from this preclinical study were compelling. The liposomal formulation demonstrated superior penetration of the active drug through the cornea compared to the standard marketed solution. In an animal model, it provided a sustained IOP reduction over a 15-day period of daily application. Perhaps most significantly, the formulation was exceptionally well-tolerated, maintaining ocular surface health at a level comparable to saline solution. This suggests a potential dual benefit: effectively treating glaucoma while simultaneously protecting or even supporting the ocular surface, a paradigm shift from merely reducing the harm caused by preservatives.

Advanced Drug Delivery Systems: The Shift Away from Eye Drops

The greatest challenge in the long-term management of glaucoma is patient adherence. The need for daily, lifelong administration of eye drops is a significant burden for many patients, and incorrect instillation technique further compromises efficacy. This has spurred a major research effort to develop delivery systems that can provide sustained drug release, removing the patient from the equation.

The most prominent example of this is the Latanoprost-eluting contact lens. This technology involves infusing a soft contact lens with a reservoir of Latanoprost, which is then released in a controlled manner over an extended period, such as one week. An active Phase I/II clinical trial (NCT04500574), sponsored by the Massachusetts Eye and Ear Infirmary, is currently evaluating the safety, tolerability, and IOP-lowering feasibility of such a device. The study employs a rigorous double-dummy, randomized design, comparing the drug-eluting lens (worn for one week) plus placebo drops against a standard, non-medicated contact lens plus standard Latanoprost drops. If proven safe and effective, this technology could revolutionize glaucoma treatment for a large segment of patients, replacing the burden of over 365 instillations per year with just 52 device applications, potentially administered by an eye care professional. This would represent a monumental step forward in solving the problem of non-adherence.

Emerging Clinical Research and Combination Therapies

The molecular frontier continues to advance with the development of new chemical entities inspired by or designed to complement Latanoprost.

• Latanoprostene Bunod (Vyzulta®): This innovative drug is a nitric oxide (NO)-donating prostaglandin analog. Following administration, it is metabolized into two distinct active moieties: latanoprost acid and butanediol mononitrate, which releases NO. This creates a powerful dual mechanism of action: the latanoprost acid increases outflow through the uveoscleral pathway, while the NO acts on the trabecular meshwork to increase outflow through the conventional pathway. This dual action has been shown in clinical trials to provide superior IOP lowering compared to either Latanoprost or timolol used as monotherapy.

Ongoing clinical trials continue to refine the use of Latanoprost and its combinations, comparing different formulations, evaluating long-term safety and efficacy, and exploring its role in various patient populations. The common thread connecting all these innovations—from preservative-free drops and FDCs to drug-eluting contact lenses—is a clear trend toward reducing the overall burden of treatment on the patient. Success in chronic disease management is increasingly defined not just by achieving a target IOP, but by achieving it with minimal disruption, discomfort, and complexity in the patient's life.

Conclusion and Expert Recommendations

Latanoprost stands as a remarkably successful and enduring therapeutic agent in the field of ophthalmology. Its development and subsequent market evolution provide a compelling case study in rational drug design, clinical efficacy, and pharmaceutical lifecycle management. Its potent IOP-lowering effect, achieved through a novel mechanism of enhancing uveoscleral outflow, combined with a highly favorable systemic safety profile, has firmly established it as a first-line therapy for open-angle glaucoma and ocular hypertension. The journey of Latanoprost from a single, innovative molecule to a mature product with a diverse portfolio of generic, value-added, and combination formulations illustrates a clear progression in therapeutic priorities.

The central clinical narrative has evolved from a singular focus on IOP reduction to a more holistic and patient-centric approach that seeks to balance efficacy with long-term tolerability and adherence. The development and adoption of preservative-free formulations and convenient fixed-dose combinations are direct reflections of this paradigm shift. The future of Latanoprost-based therapy appears to be focused on overcoming the final hurdles of topical administration through innovations in drug delivery that promise to reduce patient burden and further improve treatment outcomes.

Based on the comprehensive evidence synthesized in this report, the following expert recommendations are provided for clinicians:

• Initial Therapy: For treatment-naïve patients with OAG or OHT, a generic Latanoprost 0.005% ophthalmic solution remains an excellent and highly cost-effective first-line choice. It offers a robust and well-documented balance of IOP-lowering efficacy and good overall tolerability.
• Patient Selection and Counseling: Proactively counsel all patients initiating Latanoprost therapy on the potential for its most common and characteristic side effects, particularly the high likelihood of gradual, permanent changes in iris color and the reversible changes to eyelashes. For patients with significant pre-existing ocular surface disease, a history of preservative sensitivity, or those who develop significant irritation on a preserved formulation, an initial or subsequent switch to a preservative-free (Iyuzeh™) or BAK-free (Xelpros®) formulation is strongly recommended to improve long-term tolerability and adherence.
• Managing Inadequate IOP Response: If target IOP is not achieved with Latanoprost monotherapy, a fixed-dose combination product is a logical and potent next step. An FDC like Rocklatan® (latanoprost/netarsudil) offers superior efficacy by targeting multiple outflow pathways and has the advantage of a single-bottle regimen. However, clinicians and patients must be prepared for a higher incidence of conjunctival hyperemia compared to Latanoprost alone.
• Adherence and Future Therapies: Patient adherence remains a critical determinant of success in glaucoma management. The once-daily dosing of Latanoprost is a significant advantage that should be emphasized. For patients who demonstrate significant challenges with adherence to daily drops, clinicians should closely monitor the progress of emerging sustained-delivery technologies, such as the Latanoprost-eluting contact lens, which may offer a transformative solution in the near future.
• Contraindications and Interactions: It is crucial to adhere to the established contraindications. Specifically, clinicians must avoid the co-prescription of Latanoprost with other prostaglandin analogs, as this can lead to a paradoxical increase in IOP and is therapeutically unsound.

Works cited

1. Latanoprost: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed July 21, 2025, https://go.drugbank.com/drugs/DB00654
2. Latanoprost | C26H40O5 | CID 5311221 - PubChem, accessed July 21, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Latanoprost
3. Latanoprost Monograph for Professionals - Drugs.com, accessed July 21, 2025, https://www.drugs.com/monograph/latanoprost.html
4. GMP Latanoprost (CAS Number: 130209-82-4) - Cayman Chemical, accessed July 21, 2025, https://www.caymanchem.com/product/10011176/gmp-latanoprost
5. Latanoprost | CAS 130209-82-4 - Tocris Bioscience, accessed July 21, 2025, https://www.tocris.com/products/latanoprost_4757
6. Latanoprost - StatPearls - NCBI Bookshelf, accessed July 21, 2025, https://www.ncbi.nlm.nih.gov/books/NBK540978/
7. Latanoprost in the treatment of glaucoma | OPTH - Dove Medical Press, accessed July 21, 2025, https://www.dovepress.com/latanoprost-in-the-treatment-of-glaucoma-peer-reviewed-fulltext-article-OPTH
8. Latanoprost | CAS 130209-82-4 | SCBT - Santa Cruz Biotechnology, accessed July 21, 2025, https://www.scbt.com/p/latanoprost-130209-82-4
9. Latanoprost Ophthalmic: MedlinePlus Drug Information, accessed July 21, 2025, https://medlineplus.gov/druginfo/meds/a697003.html
10. FDA Approves Preservative-free Latanoprost Option - Review of Ophthalmology, accessed July 21, 2025, https://www.reviewofophthalmology.com/article/fda-approves-preservativefree-latanoprost-option
11. Latanoprost: uses, dosing, warnings, adverse events, interactions - MedCentral, accessed July 21, 2025, https://www.medcentral.com/drugs/monograph/14256-397003/latanoprost-ophthalmic-eye
12. Latanoprost - FDA Drug Approval Details - MedPath, accessed July 21, 2025, https://trial.medpath.com/drug/approvals/fda/388025d8004219d5
13. Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial - PMC, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10478989/
14. Xelpros (latanoprost) FDA Approval History - Drugs.com, accessed July 21, 2025, https://www.drugs.com/history/xelpros.html
15. Sun Pharma and SPARC Announce US FDA Approval of XELPROS™ to Treat Open-angle Glaucoma or Ocular Hypertension - BioSpace, accessed July 21, 2025, https://www.biospace.com/sun-pharma-and-sparc-announce-us-fda-approval-of-xelpros-to-treat-open-angle-glaucoma-or-ocular-hypertension
16. FDA approves first BAK-free formulation of latanoprost, accessed July 21, 2025, https://www.aao.org/headline/fda-approves-first-preservative-free-formulation-o
17. Iyuzeh™ (latanoprost) – New drug approval, accessed July 21, 2025, https://professionals.optumrx.com/content/dam/optum3/professional-optumrx/news/rxnews/drug-approvals/drugapproval_lyuzeh_2022-1223.pdf
18. First PF Latanoprost Eye Drop Hits the Market - Review of Optometry, accessed July 21, 2025, https://www.reviewofoptometry.com/article/first-pf-latanoprost-eye-drop-hits-the-market
19. A phase III study comparing preservative-free latanoprost eye drop emulsion with preserved latanoprost in open-angle glaucoma or ocular hypertension - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/40000909/
20. www.tcichemicals.com, accessed July 21, 2025, https://www.tcichemicals.com/MX/en/p/L0262
21. What is Latanoprost used for? - Patsnap Synapse, accessed July 21, 2025, https://synapse.patsnap.com/article/what-is-latanoprost-used-for
22. Latanoprost–Health Professional Version - StoryMD, accessed July 21, 2025, https://storymd.com/topic/Nq4ZlnBf0o-latanoprost-ophthalmic/page/LA1G7v8Und-latanoprost-health-professional-version
23. Latanoprost - Wikipedia, accessed July 21, 2025, https://en.wikipedia.org/wiki/Latanoprost
24. Latanoprost Ophthalmic - Physicians Primary Care, accessed July 21, 2025, https://www.ppcswfl.com/health-library/hw-view.php?DOCHWID=a697003
25. Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review - PMC, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2699817/
26. Meta-Analysis of Randomized Controlled Trials Comparing Latanoprost with Other Glaucoma Medications in Chronic Angle-Closure Glaucoma - ResearchGate, accessed July 21, 2025, https://www.researchgate.net/publication/264093818_Meta-Analysis_of_Randomized_Controlled_Trials_Comparing_Latanoprost_with_Other_Glaucoma_Medications_in_Chronic_Angle-Closure_Glaucoma
27. Long term effect of latanoprost on intraocular pressure in normal tension glaucoma, accessed July 21, 2025, https://www.researchgate.net/publication/8613927_Long_term_effect_of_latanoprost_on_intraocular_pressure_in_normal_tension_glaucoma
28. MD Roundtable, Part 2: Treatment of Normal-Tension Glaucoma, accessed July 21, 2025, https://www.aao.org/eyenet/article/md-roundtable-treatment-of-normal-tension-glaucoma
29. Latanoprost (ophthalmic route) - Side effects & dosage - Mayo Clinic, accessed July 21, 2025, https://www.mayoclinic.org/drugs-supplements/latanoprost-ophthalmic-route/description/drg-20064474
30. Latanoprost in the treatment of glaucoma - PMC - PubMed Central, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4196887/
31. A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost. | ClinicalTrials.gov, accessed July 21, 2025, https://clinicaltrials.gov/study/NCT00638742
32. A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of, accessed July 21, 2025, https://onderzoekmetmensen.nl/en/trial/38960
33. Characteristics and Management of Steroid-Induced Glaucoma, accessed July 21, 2025, https://www.aao.org/eyenet/article/management-of-steroid-induced-glaucoma
34. Effect of latanoprost on intraocular pressure in steroid-induced glaucoma - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/10782629/
35. Efficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocular Hypertension - ClinicalTrials.Veeva, accessed July 21, 2025, https://ctv.veeva.com/study/efficacy-of-the-brand-name-latanoprost-and-one-of-its-generic-version-in-primary-open-angle-glaucoma
36. Real-Life Study on the Efficacy and Tolerance of a Preservative-Free Surfactant-Free Latanoprost Eye Drop in Patients with Glaucoma | springermedizin.de, accessed July 21, 2025, https://www.springermedizin.de/real-life-study-on-the-efficacy-and-tolerance-of-a-preservative-/27458504
37. What is Latanoprost Ophthalmic Suspension (LATANOPROST SOLUTION, accessed July 21, 2025, https://www.columbiadoctors.org/health-library/drug-info/latanoprost-ophthalmic-suspension-latanoprost-solution-ophthalmic/
38. Latanoprost Completed Phase 4 Trials for Macular Edema, Cystoid / Anterior Uveitis (AU) Treatment | DrugBank Online, accessed July 21, 2025, https://go.drugbank.com/drugs/DB00654/clinical_trials?conditions=DBCOND0081707%2CDBCOND0027867&phase=4&purpose=treatment&status=completed
39. Latanoprost: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 21, 2025, https://www.rxlist.com/latanoprost/generic-drug.htm
40. Efficacy and tolerability of bimatoprost versus travoprost in patients ..., accessed July 21, 2025, https://bjo.bmj.com/content/94/1/74
41. Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03 ..., accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4179117/
42. Comparison of the Effects of Latanoprost, Travoprost, and Bimatoprost on Circadian Intraocular Pressure in Patients with Glaucoma or Ocular Hypertension | Request PDF - ResearchGate, accessed July 21, 2025, https://www.researchgate.net/publication/7316348_Comparison_of_the_Effects_of_Latanoprost_Travoprost_and_Bimatoprost_on_Circadian_Intraocular_Pressure_in_Patients_with_Glaucoma_or_Ocular_Hypertension
43. A Comparison of Latanoprost, Bimatoprost, and Travoprost in Patients With Elevated Intraocular Pressure: A 12-week, Randomized, - OphEd, accessed July 21, 2025, https://www.ophed.net/system/files/2012/10/xlt-3555-3555.pdf
44. A Study of Glaucoma or Ocular Hypertension in Patients Within the United States | ClinicalTrials.gov, accessed July 21, 2025, https://clinicaltrials.gov/study/NCT00800267
45. Efficacy of Morning Versus Evening Latanoprost/Timolol Fixed Combination for Open-Angle Glaucoma and Ocular Hypertension: A Randomized Clinical Trial | TVST, accessed July 21, 2025, https://tvst.arvojournals.org/article.aspx?articleid=2793321
46. Rocklatan (netarsudil and latanoprost) FDA Approval History - Drugs.com, accessed July 21, 2025, https://www.drugs.com/history/rocklatan.html
47. An overview of new glaucoma medications - EyeWorld, accessed July 21, 2025, https://www.eyeworld.org/2020/an-overview-of-new-glaucoma-medications/
48. Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/35989070/
49. Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/39867351/
50. Cost-effectiveness of latanoprost, travoprost and bimatoprost for the treatment of glaucoma in Norway, Sweden and Denmark, using a decision-analytic health economic model | Request PDF - ResearchGate, accessed July 21, 2025, https://www.researchgate.net/publication/289392169_Cost-effectiveness_of_latanoprost_travoprost_and_bimatoprost_for_the_treatment_of_glaucoma_in_Norway_Sweden_and_Denmark_using_a_decision-analytic_health_economic_model
51. Cost effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom using a decision-analytic health economic model Response | Request PDF - ResearchGate, accessed July 21, 2025, https://www.researchgate.net/publication/6117861_Cost_effectiveness_of_latanoprost_and_timolol_maleate_for_the_treatment_of_glaucoma_in_Scandinavia_and_the_United_Kingdom_using_a_decision-analytic_health_economic_model_Response
52. Cost-minimization analysis of bimatoprost 0.03%, latanoprost 0.005% - ResearchGate, accessed July 21, 2025, https://www.researchgate.net/figure/Cost-minimization-analysis-of-bimatoprost-003-latanoprost-0005-and-travoprost_tbl2_5945126
53. Cost-effectiveness of prostaglandin analogues in Brazil - Revista Brasileira de Oftalmologia, accessed July 21, 2025, https://www.rbojournal.org/en/article/cost-effectiveness-of-prostaglandin-analogues-in-brazil/
54. Economic impact of initial glaucoma treatment with selective laser trabeculoplasty on the Brazilian Public Health System - SciELO, accessed July 21, 2025, https://www.scielo.br/j/abo/a/3tj5sfXnbwgstWsYkZwF8wF/?lang=en
55. March in Xalatan - NIH technology transfer, accessed July 21, 2025, https://www.techtransfer.nih.gov/sites/default/files/documents/policy/March-in-xalatan.pdf
56. Generic Xalatan Availability - Drugs.com, accessed July 21, 2025, https://www.drugs.com/availability/generic-xalatan.html
57. Safety and efficacy of topically administered netarsudil-latanoprost fixed dose combination (FDC) (Rocklatan™) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG) - PubMed Central, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8633047/
58. Generic Xelpros Availability - Drugs.com, accessed July 21, 2025, https://www.drugs.com/availability/generic-xelpros.html
59. FDA Clears New Form of Latanoprost (Xelpros) for Glaucoma - Medscape, accessed July 21, 2025, https://www.medscape.com/viewarticle/902233
60. Approval Package - accessdata.fda.gov, accessed July 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/208259Orig1s000Approv.pdf
61. Iyuzeh (latanoprost) FDA Approval History - Drugs.com, accessed July 21, 2025, https://www.drugs.com/history/iyuzeh.html
62. Xelpros™ (latanoprost ophthalmic emulsion) – New formulation approval, accessed July 21, 2025, https://professionals.optumrx.com/publications/library/drugapprovals_xelpros_2018-0917.html
63. Disclosing long-term tolerance, efficacy and penetration properties of hyaluronic acid-coated latanoprost-loaded liposomes as chronic glaucoma therapy - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/39832744/
64. Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular ..., accessed July 21, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT04500574/latanoprost-eluting-contact-lens-for-treating-glaucoma-and-ocular-hypertension
65. Study Details | Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension | ClinicalTrials.gov, accessed July 21, 2025, https://clinicaltrials.gov/study/NCT04500574
66. GETTING TO GOAL - New York Eye and Ear Infirmary, accessed July 21, 2025, https://www.nyee.edu/files/NYEE/Education/195-AAO-2019_B-L-Glaucoma-Monograph.pdf
67. Latanoprost Completed Phase 1 Trials for Open Angle Glaucoma (OAG) / Ocular Hypertension Treatment | DrugBank Online, accessed July 21, 2025, https://go.drugbank.com/drugs/DB00654/clinical_trials?conditions=DBCOND0074237%2CDBCOND0046770&phase=1&purpose=treatment&status=completed
68. Latanoprost Completed Phase 2 Trials for Open Angle Glaucoma or Ocular Hypertension Treatment | DrugBank Online, accessed July 21, 2025, https://go.drugbank.com/drugs/DB00654/clinical_trials?conditions=DBCOND0051989&phase=2&purpose=treatment&status=completed
69. Latanoprost Completed Phase 4 Trials for Primary Open-Angle Glaucoma / Ocular Hypertension Treatment - DrugBank, accessed July 21, 2025, https://go.drugbank.com/drugs/DB00654/clinical_trials?conditions=DBCOND0074237%2CDBCOND0046963&phase=4&purpose=treatment&status=completed